GLP1R and Blindness: The incidence of all-cause blindness was even less often coded in those patients who had preexisting DR and received GLP-1 RA prescriptions compared with those without GLP-1 RA prescriptions (1280 [3.9%] vs 1833 [5.6%] events; HR, 0.70 [95% CI, 0.65-0.75], P < .001; Z = −2.166, P = .02), a 30.2% relative risk reduction in blindness.